DK3463345T3 - Farmaceutiske kombinationer - Google Patents

Farmaceutiske kombinationer Download PDF

Info

Publication number
DK3463345T3
DK3463345T3 DK17807555.2T DK17807555T DK3463345T3 DK 3463345 T3 DK3463345 T3 DK 3463345T3 DK 17807555 T DK17807555 T DK 17807555T DK 3463345 T3 DK3463345 T3 DK 3463345T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical combinations
pharmaceutical
combinations
Prior art date
Application number
DK17807555.2T
Other languages
English (en)
Inventor
Giordano Caponigro
Zhu Alexander Cao
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60477982&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3463345(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Application granted granted Critical
Publication of DK3463345T3 publication Critical patent/DK3463345T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
DK17807555.2T 2016-06-03 2017-06-02 Farmaceutiske kombinationer DK3463345T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662345389P 2016-06-03 2016-06-03
PCT/US2017/035653 WO2017210538A1 (en) 2016-06-03 2017-06-02 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
DK3463345T3 true DK3463345T3 (da) 2023-01-09

Family

ID=60477982

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17807555.2T DK3463345T3 (da) 2016-06-03 2017-06-02 Farmaceutiske kombinationer

Country Status (26)

Country Link
US (3) US10485788B2 (da)
EP (1) EP3463345B1 (da)
JP (2) JP6805336B2 (da)
KR (1) KR102439911B1 (da)
CN (1) CN109890386B (da)
AU (1) AU2017275650B2 (da)
BR (1) BR112018074941A2 (da)
CA (1) CA3026361A1 (da)
CL (1) CL2018003421A1 (da)
CO (1) CO2019000010A2 (da)
CR (1) CR20190002A (da)
DK (1) DK3463345T3 (da)
FI (1) FI3463345T3 (da)
HU (1) HUE060653T2 (da)
IL (1) IL263431A (da)
MA (1) MA45187A (da)
MX (1) MX2018014973A (da)
PH (1) PH12018502549A1 (da)
PL (1) PL3463345T3 (da)
PT (1) PT3463345T (da)
RU (1) RU2759669C2 (da)
SG (1) SG11201810793XA (da)
SI (1) SI3463345T1 (da)
UA (1) UA125436C2 (da)
WO (1) WO2017210538A1 (da)
ZA (1) ZA201900019B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201810793XA (en) 2016-06-03 2018-12-28 Giordano Caponigro Pharmaceutical combinations
US10973829B2 (en) * 2016-09-19 2021-04-13 Novartis Ag Therapeutic uses of a C-RAF inhibitor
CA3150474A1 (en) * 2019-10-11 2021-04-15 Geraint Iwan Davies DRUG DOSAGE DETERMINATION DEVICES AND METHODS
EP4103286A4 (en) * 2020-02-10 2024-03-20 Cedars Sinai Medical Center METHOD FOR TREATING PANCREATIC CANCER
JP7288220B2 (ja) 2021-03-29 2023-06-07 ダイキン工業株式会社 モータ、送風装置、および冷凍装置
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
SG148857A1 (en) 2002-03-13 2009-01-29 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
MX2011000738A (es) 2008-07-24 2011-02-23 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inhibidoers de proteina cinasa.
JP5527878B2 (ja) * 2009-07-30 2014-06-25 トムソン ライセンシング 表示装置及び音声出力装置
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
WO2012170715A1 (en) * 2011-06-07 2012-12-13 Caris Mpi, Inc. Molecular profiling for cancer
CA2855243C (en) * 2011-11-11 2020-04-14 Novartis Ag Method of treating a proliferative disease
CN105708819B (zh) 2011-11-23 2020-12-29 诺华股份有限公司 医药制剂
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
PT2882440T (pt) 2012-08-07 2019-04-23 Array Biopharma Inc Combinações farmacêuticas compreendendo um inibidor de braf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa
LT3702351T (lt) 2012-10-19 2024-01-10 Array Biopharma, Inc. Kompozicijos, apimančios mek inhibitorių
BR112015009134A2 (pt) * 2012-10-25 2017-07-04 Glaxosmithkline Llc combinação
SG10201906270VA (en) 2013-03-21 2019-08-27 Novartis Ag Combination therapy comprising a b-raf inhibitor and a second inhibitor
US9447013B2 (en) * 2013-07-18 2016-09-20 Daicel Corporation Method for producing oxide
US20150087279A1 (en) * 2013-09-20 2015-03-26 Better Mousetrap, LLC Mobile accident processing system and method
WO2015087279A1 (en) * 2013-12-12 2015-06-18 Glaxosmithkline Intellectual Property (No.2) Limited Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
WO2016155670A1 (zh) * 2015-04-01 2016-10-06 苏州晶云药物科技有限公司 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
WO2017019279A1 (en) 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
SG11201810793XA (en) 2016-06-03 2018-12-28 Giordano Caponigro Pharmaceutical combinations

Also Published As

Publication number Publication date
KR20190119507A (ko) 2019-10-22
MA45187A (fr) 2019-04-10
PL3463345T3 (pl) 2023-02-06
FI3463345T3 (fi) 2023-01-31
CO2019000010A2 (es) 2019-05-21
RU2018146812A (ru) 2020-07-09
RU2018146812A3 (da) 2020-10-09
IL263431A (en) 2019-01-31
ZA201900019B (en) 2023-04-26
KR102439911B1 (ko) 2022-09-05
SG11201810793XA (en) 2018-12-28
EP3463345A1 (en) 2019-04-10
EP3463345A4 (en) 2020-02-26
JP6805336B2 (ja) 2020-12-23
EP3463345B1 (en) 2022-11-02
CN109890386B (zh) 2022-05-24
JP2019525948A (ja) 2019-09-12
US11376239B2 (en) 2022-07-05
BR112018074941A2 (pt) 2019-03-12
CR20190002A (es) 2019-06-10
US20230044943A1 (en) 2023-02-09
SI3463345T1 (sl) 2023-02-28
US10485788B2 (en) 2019-11-26
US20200230108A1 (en) 2020-07-23
RU2759669C2 (ru) 2021-11-16
AU2017275650B2 (en) 2023-06-01
PT3463345T (pt) 2023-01-06
HUE060653T2 (hu) 2023-04-28
US20190105303A1 (en) 2019-04-11
MX2018014973A (es) 2019-12-18
CL2018003421A1 (es) 2019-07-19
PH12018502549A1 (en) 2019-04-08
UA125436C2 (uk) 2022-03-09
WO2017210538A1 (en) 2017-12-07
AU2017275650A1 (en) 2019-01-17
CA3026361A1 (en) 2017-12-07
JP2021054832A (ja) 2021-04-08
CN109890386A (zh) 2019-06-14

Similar Documents

Publication Publication Date Title
DK3405050T3 (da) Børnesikret snusbeholder
DK3436823T3 (da) Antigen-array
DK3529240T3 (da) Farmaceutiske forbindelser
DK3445708T3 (da) Stigbøjle
DK3402792T3 (da) Quinolin-2-on-derivater
DK3335532T3 (da) Tandharve
DK3509963T3 (da) Pallecontainer
DK3463345T3 (da) Farmaceutiske kombinationer
ES2841649T5 (es) Composición farmacéutica
DK3528829T3 (da) Bacitracin-alginat-oligomer-konjugater
DK3575238T3 (da) Pallecontainer
DE112017006386A5 (de) Schraubarbeitszylinder
DE112017000734A5 (de) Glycolsensor
DK3471535T3 (da) Dyrelift
DK3323708T3 (da) Bovfender
DK3452590T3 (da) Plademagnet
DK3452587T3 (da) Penicillin-g-acylaser
DK3295800T3 (da) Sandwichkiksindretning
DK3288967T3 (da) Farmaceutisk forbindelse
DE112017006474A5 (de) Gargerätevorrichtung
DK3551954T3 (da) Rekuperator
DE112017005767A5 (de) Nasslaufende lamellenkupplung
DK3468607T3 (da) Resveratrolsolubilisat
DK3430609T3 (da) Smartflag
DE112017000296A5 (de) Radgeschwindigkeitssensorvorrichtung